| 1081/1644 | US=67 / Biol/Mol Perales MA, Wolchok JD, Kaufman HL. Vaccines as targeted cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 447-69. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. |
| 1082/1644 | US=67 / Biol/Mol Koon HB, Atkins MB. Cytokine-based therapy for cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 471-507. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER. TERAPIA; CITOQUINA; INTERFERON; INTERLEUCINA; IMUNOTERAPIA; RESISTENCIA; LEUCEMIA DE CELULAS PILOSAS; LEUCEMIA MIELOIDE CRONICA; LINFOMA NAO-HODGKIN; MELANOMA; CARCINOMA DE CELULAS RENAIS; SARCOMA DE KAPOSI |
| 1083/1644 | US=67 / Biol/Mol Bertagnolli M, Viner JL, Hawk ET. Cyclooxygenase-2 as a target for cancer prevention and treatment. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 509-41. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CICLOOXIGENASE-2; COX-2; CANCER. PREVENCAO; CANCER. TRATAMENTO; INFLAMACAO; PROSTAGLANDINA; TUMORIGENESE |
| 1084/1644 | US=67 / Biol/Mol Denis GV. Imatinib mesylate (gleevec) and the emergence of chemotherapeutic drug-resistant mutations. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 545-57. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. QUIMIOTERAPICOS; MUTACOES; RESISTENCIA AOS MEDICAMENTOS; MESILATO DE IMATINIBE; GLEEVEC; STI-571; LEUCEMIA MIELOGENA CRONICA; TUMOR ESTROMAL GASTROINTESTINAL; BCR-ABL; C-KIT; FATOR DE CELULA-TRONCO; BIOLOGIA ESTRUTURAL |
| 1085/1644 | US=67 / Biol/Mol Mendelsohn J. Development of a targeted treatment for cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 559-71. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER; TERAPIA; FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; CETUXIMABE; TIROSINA QUINASE; ANTICORPO MONOCLONAL C225 |
| 1086/1644 | US=67 / Biol/Mol Saini S, Hurwitz H. VEGF inhibition for cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 573-84. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. INIBICAO DO VEGF; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; TERAPIA DO CANCER; ANTI-ANGIOGENESE; INIBICAO DA QUINASE DE TIROSINA; BEVACIZUMABE; SORAFENIBE; BAY 43-9006; MALATO DE SUNITINIBE; SU11248; VATALANIBE |
| 1087/1644 | US=67 / Biol/Mol Champaneria MC, Modlin IM, Latich I, Bornschein J, Drozdov I, Kidd M. Somatostatin analogue therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 585-637. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. TERAPIA ANALOGA DA SOMATOSTATINA; ACROMEGALIA; CARCINOIDE; SINDROME CARCINOIDE; HORMONIO DE CRESCIMENTO; LUTECIO; OCTREOTIDE; NEUROENDOCRINO; PROLIFERACAO; CINTILOGRAFIA; RECEPTOR DE SOMATOSTATINA; SOMATULINA; TUMOR; ITRIO |
| 1088/1644 | US=67 / Biol/Mol Dy GK, Adjei AA. Patient selection for rational development of novel anticancer agents. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 641-8. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. AGENTES ANTICANCERIGENOS; SELECAO DOS PACIENTES; TERAPIA-ALVO; BIOMARCADORES; EXPRESSAO GENICA; AMPLIFICACAO GENICA |
| 1089/1644 | US=67 / Biol/Mol Dubey S, Schiller JH. Clinical trial design with targeted agents. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 649-55. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. ESTUDO CLINICO; AGENTES DIRECIONADOS; ENSAIOS CLINICOS; AGENTES ALVOS |
| 1090/1644 | US=67 / Biol/Mol Kitzen JJEM, de Jonge MJA, Verweij J. How to define treatment sucess or failure if tumors do not shrink: consequences for trial design. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 657-74. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. MARCADOR SUBSTITUTO; TECIDO SUBSTITUTO; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; INIBIDOR DA FARNESIL TRANSFERASE; SELECAO DE PACIENTE; IMAGEM; PROJETO DESCONTINUACAO RANDOMIZADO; INDICE DE MODULACAO DO CRESCIMENTO; TAXA DE PROGRESSAO; TAXA LIVRE DE PROGRESSAO |
| 1091/1644 | US=67 / Biol/Mol Shankar LK, Menkens A, Sullivan DC. Molecular imaging in oncology. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 675-91. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. ONCOLOGIA; IMAGEM MOLECULAR; BIOMARCADORES DE IMAGEM; BIOMARCADORES IN VIVO; TESTES DE CANCER; PROCESSO NEOPLASICO; AGENTES PET; CONTRASTE AGENTES MR; TECNOLOGIA OPTICA |
| 1092/1644 | US=67 / Biol/Mol Chen HX, Dancey JE. Combinations of molecular-targeted therapies: opportunities and challenges. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 693-705. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. |
| 1093/1644 | US=67 / Biol/Mol Tomaszewski JE, Doroshow JH. Preclinical development of molecularly targeted agents in oncology. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 707-22. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. ONCOLOGIA; DESENVOLVIMENTO PRE-CLINICO; AGENTES ALVO MOLECULARES; AGENTES ANTITUMORAIS; DESENVOLVIMENTO DE DROGAS; ALVOS MOLECULARES; FARMACOCINETICA; FARMACODINAMICA; TOXICOLOGIA |
| 1094/1644 | US=67 / Imagem Baer TM, Mulshine JL. Biomedical imaging archive network. In: Mulshine JL, Baer TM. Quantitative imaging tools for lung cancer drug assessment. New Jersey: John Wiley & Sons, 2008. p. 131-40. ISBN 978-0-470-11880-1. IMAGEM BIOMEDICA; ARQUIVO DE REDE; BASES DE DADOS; BIOLOGIA MOLECULAR; IMAGEM QUANTITATIVA |
| 1095/1644 | US=69 / Câncer Zhou Y, Alexanian R, Wang M. Targeted therapy in multiple myeloma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 213-36. ISBN 978-1-60327-423-4. TERAPIA-ALVO; MIELOMA MULTIPLO; PATOGENESE MOLECULAR; MICROAMBIENTE |
| 1096/1644 | US=69 / Câncer Ludwing J, Trent JC. Targeted therapy of sarcoma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 317-34. ISBN 978-1-60327-423-4. TERAPIA-ALVO DE SARCOMA; SARCOMA; MOLECULAR; ALVO; TERAPIA PERSONALIZADA |
| 1097/1644 | US=69 / Câncer Kundra V, Schellingerhout D, Jackson EF. Targeted and functional imaging. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 335-60. ISBN 978-1-60327-423-4. IMAGEM ALVO; IMAGEM FUNCIONAL; IMAGEM MOLECULAR; SPECT; PET; MR; DCE-MR |
| 1098/1644 | US=58 / Câncer Pevarello P, Bischoff JR, Mercurio C. Targeting cyclin-dependent kinases with small molecular inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 235-44. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CICLINA DEPENDENTE DE QUINASE; INIBIDOR DE MOLECULA PEQUENA; SELETIVIDADE; DE MULTI-ALVO; ENSAIOS CLINICOS |
| 1099/1644 | US=8 / Dermatologia Hsieh FH, Brigham CO, Austen KF. The molecular and cellular biology of the mast cell. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editores. Fitzpatrick's dermatology in general medicine. 6th ed. New York: McGraw-Hill, 2008. p. 330-5. ISBN 978-0-07138076-0. MASTOCITO; BIOLOGIA MOLECULAR; BIOLOGIA CELULAR; RECEPTORES DE CELULAS MASTRO; LIGANTES; QUIMIOTAXIA |
| 1100/1644 | US=9 / Estatística Khoury MJ, Millikan R, Gwinn M. Special topics: genetic and molecular epidemiology. In: Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia: Lippincott Wiilians & Wilkins, 2008. p. 564-79. ISBN 978-0-7817-5564-1. EPIDEMIOLOGIA GENETICA; EPIDEMIOLOGIA MOLECULAR; AVALIACAO DE BIOMARCADORES; ESTUDOS EPIDEMIOLOGICOS CONVENCIONAIS; QUESTOES METODOLOGICAS; ESTUDOS EPIDEMIOLOGICOS NAO CONVENCIONAIS |